RAS

In molecular biology, '''Ras''' is the name of a protein, the gene that encodes it, and the family and superfamily of proteins to which it belongs. The Ras superfamily of small GTPases includes the Ras, Rho, Arf, Rab, and Ran families.

Contents

Functions

Activated and inactivated forms

Attachments

Ras in cancer

Inappropriate activation of the gene

Constitutively active Ras

Drug targeting

References

External links

Functions

Proteins in the Ras family are very important molecular switches for a wide variety of signal pathways that control such processes as cytoskeletal integrity, proliferation, cell adhesion, apoptosis, and cell migration.
Ras and ras-related proteins are often deregulated in cancers, leading to increased invasion and metastasis, and decreased apoptosis.
RAS activates a number of pathways but an especially important one seems to be the mitogen-activated protein (MAP) kinases, which themselves transmit signals downstream to other protein kinases and gene regulatory proteins.^[1]

Activated and inactivated forms

RAS is a G protein (specifically a small GTPase): a regulatory GTP hydrolase that cycles between two conformations – an activated or inactivated form, respectively RAS-GTP and RAS-GDP.
It is ''activated'' by guanine exchange factors (GEFs, eg. CDC25, SOS1 and SOS2, SDC25 in yeast), which are themselves activated by mitogenic signals and through feedback from Ras itself. A GEF usually heightens the dissociation rate of the nucleotide – while not changing the association rate (effectively lower the affinity of the nucleotide) – thereby promoting its exchange. The cellular concentration of GTP is much higher than this of GDP so the exchange is usually GDP vs. GTP.
It is ''inactivated'' by GTPase-activating proteins (GAPs, the most frequently cited one being RasGAP), which increase the rate of GTP hydrolysis, returning RAS to its GDP-bound form, simultaneously releasing an inorganic phosphate.

Attachments

Ras is attached to the cell membrane by prenylation, and in health is a key component in many pathways which couple growth factor receptors to downstream mitogenic effectors involved in cell proliferation or differentiation.^[2] The C-terminal CaaX box of Ras first gets farnesylated at its Cys residue in the cytosol and then inserted into the membrane of the endoplasmatic reticulum. The Tripeptid (aaX) is then cleaved from the C-terminus by a specific prenyl-protein specific endoprotease, the new C-terminus is the methylated by a methyltransferase. The so processed Ras is now transported to the plasmamembrane. Most Ras forms are now further palmityolated, while K-Ras with its long positively charged stretch interacts electrostaticly with the membrane.

Ras in cancer

Mutations in the Ras family of proto-oncogenes (comprising H-Ras, N-Ras and K-Ras) are very common, being found in 20% to 30% of all human tumours.^[3]

Inappropriate activation of the gene

Inappropriate activation of the gene has been shown to play a key role in signal transduction, proliferation and malignant transformation.^[4]
Mutations in a number of different genes as well as RAS itself can have this effect. Oncogenes such as p210BCR-ABL or the growth receptor erbB are upstream of Ras, so if they are constitutively activated their signals will transduce through Ras.
The tumour suppressor gene NF1 encodes a Ras-GAP – its mutation in neurofibromatosis will mean that Ras is less likely to be inactivated. Ras can also be amplified, although this only occurs occasionally in tumours.
Finally, Ras oncogenes can be activated by point mutations so that its GTPase reaction can no longer be stimulated by GAP – this increases the half life of active Ras-GTP mutants.^[5]

Constitutively active Ras

''Constitutively active Ras'' (''Ras^D'') is one which contains mutations that prevent GTP hydrolysis, thus locking Ras in a permanently 'On' state.
The most common mutations are found at residue G12 in the P-loop and the catalytic residue Q61.

★ The glycine to valine mutation at ''residue 12'' renders Ras insensitive to inactivation by GAP and thus stuck in the "on state". Ras requires a GAP for inactivation as it is a relatively poor catalyst on its own, as opposed to other G-domain-containing proteins such as the alpha subunit of heterotrimeric G proteins.

★ ''Residue 61''^[6] is responsible for stabilizing the transition state for GTP hydrolysis. Because enzyme catalysis in general is achieved by lowering the energy barrier between substrate and product, mutation of Q61 necessarily reduces the rate of intrinsic Ras GTP hydrolysis to physiologically meaningless levels.
See also "dominant negative" mutants such as S17N and D119N.

Drug targeting

Because it is central in so many pathways, and prominent in so many tumours it would be extremely useful if a drug was found which could reintroduce regulation in to the RAS system, or kill cells with uncontrolled RAS pathways.
Ideally a drug targeting Ras would be able to distinguish between its oncogene and the normal homolog - simply targeting all cells with Ras would also affect normal cells, producing toxic side effects. However the differences between these molecules are very slight (resulting from single amino acid changes) and this might prove a very difficult task.
Instead, other approaches have been investigated, including targeting the processes responsible for prenylating Ras with the farnesyltransferase inhibitors.

References

1. Molecular cell biology, Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J, , , W.H. Freeman, 2000, ISBN 0-7167-3706-X
2. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?, Reuter C, Morgan M, Bergmann L, , , Blood, 2000
3. ras oncogenes in human cancer: a review., Bos J, , , Cancer Res, 1989
4.
5.
6. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=164790&a=164790_AllelicVariant0002

External links

★ "Brain tumour findings offer hope of new strategy Canadian Cancer Society says" at ncic.cancer.ca

★ "Novel cancer treatment gets NCI support" at arstechnica.com

★

★